Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04278287 | Chemoradiotherapy in Unresectable Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06718205 | Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 112 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Dec 5, 2024 |
| clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | recruiting | Phase 2 | 188 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer(BAH250) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06681285 | Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)(CAR-RMEC) | not yet recruiting | Phase 2 | 51 | Hebei Medical University Fourth HospitalOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06663059 | Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study | recruiting | Phase 2 | 80 | Tang-Du HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 147 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586242 | Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy(EASOPCWAAC) | recruiting | Phase 2 | 194 | Xijing HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588335 | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Henan Provincial People's HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06598917 | Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT | not yet recruiting | Phase 2 | 60 | China Medical University HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06599775 | Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer | not yet recruiting | Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05628610 | Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 13, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04554771 | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy(BASALT) | active not recruiting | Phase 2 | 41 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06508229 | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 | 65 | Harbin Medical UniversityOTHER | 0 | Jul 18, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06413342 | Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 191 | Zhejiang Cancer HospitalOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 70 | Rui-hua Xu, MD, PhDOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06385730 | Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)(BLESS) | recruiting | Phase 2 | 60 | Shanghai Chest HospitalOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06469060 | Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction(TRACE) | not yet recruiting | Phase 2 | 34 | Shanghai Chest HospitalOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478264 | A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma | not yet recruiting | Phase 2 | 40 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 27, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06468644 | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06468670 | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06084897 | Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy | recruiting | Phase 2 | 120 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06429839 | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | recruiting | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT06426797 | Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 25 | Peking University People's HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06410651 | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06354218 | Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06304350 | Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Tongji UniversityOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06187597 | Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)(EC-CRT-007) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06178211 | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | not yet recruiting | Phase 2 | 36 | Shanghai Chest HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06122493 | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Nov 8, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 13, 2024source: clinicaltrials